In 371 Japanese patients with insomnia randomised to open-label vornorexant 5 mg or 10 mg for up to 52 weeks, nasopharyngitis (10.9%, 8.2%) and somnolence (5.4%, 12.0%) were most common; no concerning withdrawal or rebound insomnia, and diary sleep latency fell by 32–44 min.
RCTn = 371
Uchimura et al. Long-term safety and efficacy of vornorexant in Japanese patients with insomnia: A 52-week open-label, randomized trial